CARA - Cara Therapeutics down 8% after hours following Q4 2021 earnings misses
Shares of Cara Therapeutics (NASDAQ:CARA) are down 8% in after-hours trading after the company's Q4 2021 results missed on the top and bottom lines. In the quarter, the company swung to a net loss of $33.4M from net income of $78.9M in the year-ago period. Diluted EPS in the quarter was -$0.63 compared to $1.59 in Q4 2020. Revenue of $820K was a 99% year-over-year drop. Looking ahead, Cara (CARA) expects to launch Korsuva (difelikefalin) in the U.S. in April for moderate-to-severe pruritus associated with chronic kidney disease. This quarter, the company expects to start a phase 3 trial of oral Korsuva for atopic dermatitis. Cara (CARA) said its $236.8M in cash at the end of the year is enough to fund it through 2023. Read why Seeking Alpha contributor Aquarius Research considers Cara (CARA) a strong buy.
For further details see:
Cara Therapeutics down 8% after hours following Q4 2021 earnings misses